# UNITED THERAPEUTICS Corp: overview

UTHR · Nasdaq · CIK 1082554 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/uthr.md) · [Financials](/companies/uthr/financials.md) · [Filings](/companies/uthr/filings.md) · [Insiders](/companies/uthr/insiders.md)

Latest reported revenue: [$783.3m](/filings/0001082554-26-000027.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001082554-26-000027).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [749](/filings/0001082554-25-000034.md) | [736 d](/filings/0001082554-26-000006.md) | [794](/filings/0001082554-26-000020.md) | [799](/filings/0001082554-26-000027.md) | [800](/filings/0001082554-25-000034.md) | [790 d](/filings/0001082554-26-000006.md) | [782](/filings/0001082554-26-000020.md) | [783](/filings/0001082554-26-000027.md) |
| Gross margin | % | [88.9%](/filings/0001082554-25-000034.md) | [89.7% d](/filings/0001082554-26-000006.md) | [88.4%](/filings/0001082554-26-000020.md) | [89.0%](/filings/0001082554-26-000027.md) | [87.4%](/filings/0001082554-25-000034.md) | [86.9% d](/filings/0001082554-26-000006.md) | [82.9%](/filings/0001082554-26-000020.md) | [87.3%](/filings/0001082554-26-000027.md) |
| Operating margin | % | [45.8%](/filings/0001082554-25-000034.md) | [48.6% d](/filings/0001082554-26-000006.md) | [48.2%](/filings/0001082554-26-000020.md) | [45.6%](/filings/0001082554-26-000027.md) | [48.6%](/filings/0001082554-25-000034.md) | [45.1% d](/filings/0001082554-26-000006.md) | [41.7%](/filings/0001082554-26-000020.md) | [42.2%](/filings/0001082554-26-000027.md) |
| Net margin | % | [41.3%](/filings/0001082554-25-000034.md) | [40.9% d](/filings/0001082554-26-000006.md) | [40.6%](/filings/0001082554-26-000020.md) | [38.8%](/filings/0001082554-26-000027.md) | [42.4%](/filings/0001082554-25-000034.md) | [46.1% d](/filings/0001082554-26-000006.md) | [35.2%](/filings/0001082554-26-000020.md) | [42.5%](/filings/0001082554-26-000027.md) |
| Diluted EPS | $ per share | [6.39](/filings/0001082554-25-000034.md) | not reported | [6.63](/filings/0001082554-26-000020.md) | [6.41](/filings/0001082554-26-000027.md) | [7.16](/filings/0001082554-25-000034.md) | not reported | [5.82](/filings/0001082554-26-000020.md) | [7.27](/filings/0001082554-26-000027.md) |
| Free cash flow | $m | [301 d](/filings/0001082554-25-000034.md) | [255 d](/filings/0001082554-26-000006.md) | [386](/filings/0001082554-26-000020.md) | [130 d](/filings/0001082554-26-000027.md) | [352 d](/filings/0001082554-25-000034.md) | [173 d](/filings/0001082554-26-000006.md) | [363](/filings/0001082554-26-000020.md) | [206 d](/filings/0001082554-26-000027.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,686](/filings/0001082554-24-000005.md) | [1,936](/filings/0001082554-25-000005.md) | [2,328](/filings/0001082554-26-000006.md) | [2,877](/filings/0001082554-26-000006.md) | [3,183](/filings/0001082554-26-000006.md) |
| Gross margin | % | [92.7%](/filings/0001082554-24-000005.md) | [92.2%](/filings/0001082554-25-000005.md) | [88.9%](/filings/0001082554-26-000006.md) | [89.2%](/filings/0001082554-26-000006.md) | [87.9%](/filings/0001082554-26-000006.md) |
| Operating margin | % | [33.0%](/filings/0001082554-24-000005.md) | [50.6%](/filings/0001082554-25-000005.md) | [50.9%](/filings/0001082554-26-000006.md) | [47.9%](/filings/0001082554-26-000006.md) | [46.9%](/filings/0001082554-26-000006.md) |
| Net margin | % | [28.2%](/filings/0001082554-24-000005.md) | [37.6%](/filings/0001082554-25-000005.md) | [42.3%](/filings/0001082554-26-000006.md) | [41.5%](/filings/0001082554-26-000006.md) | [41.9%](/filings/0001082554-26-000006.md) |
| Diluted EPS | $ per share | [10.06](/filings/0001082554-24-000005.md) | [15.00](/filings/0001082554-25-000005.md) | [19.81](/filings/0001082554-26-000006.md) | [24.64](/filings/0001082554-26-000006.md) | [27.86](/filings/0001082554-26-000006.md) |
| Free cash flow | $m | [477](/filings/0001082554-24-000005.md) | [664](/filings/0001082554-25-000005.md) | [748](/filings/0001082554-26-000006.md) | [1,081](/filings/0001082554-26-000006.md) | [1,041](/filings/0001082554-26-000006.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/uthr/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-10-28 | [Rothblatt Martine a](/insiders/1106578.md) | Chairperson & CEO, Director, Officer | Sale (S) | 80 | $588.3913 | $47.1k | [Form 4](/filings/0001106578-26-000174.md) |
| 2026-10-28 | [Rothblatt Martine a](/insiders/1106578.md) | Chairperson & CEO, Director, Officer | Sale (S) | 986 | $587.2653 | $579.0k | [Form 4](/filings/0001106578-26-000174.md) |
| 2026-10-28 | [Rothblatt Martine a](/insiders/1106578.md) | Chairperson & CEO, Director, Officer | Sale (S) | 3,086 | $586.3694 | $1.8m | [Form 4](/filings/0001106578-26-000174.md) |
| 2026-10-28 | [Rothblatt Martine a](/insiders/1106578.md) | Chairperson & CEO, Director, Officer | Sale (S) | 1,902 | $585.3585 | $1.1m | [Form 4](/filings/0001106578-26-000174.md) |
| 2026-10-28 | [Rothblatt Martine a](/insiders/1106578.md) | Chairperson & CEO, Director, Officer | Sale (S) | 2,625 | $584.4314 | $1.5m | [Form 4](/filings/0001106578-26-000174.md) |
| 2026-10-28 | [Rothblatt Martine a](/insiders/1106578.md) | Chairperson & CEO, Director, Officer | Sale (S) | 821 | $583.5017 | $479.1k | [Form 4](/filings/0001106578-26-000174.md) |
| 2026-10-27 | [Rothblatt Martine a](/insiders/1106578.md) | Chairperson & CEO, Director, Officer | Sale (S) | 80 | $592.835 | $47.4k | [Form 4](/filings/0001106578-26-000173.md) |
| 2026-10-27 | [Rothblatt Martine a](/insiders/1106578.md) | Chairperson & CEO, Director, Officer | Sale (S) | 600 | $592.054 | $355.2k | [Form 4](/filings/0001106578-26-000173.md) |
| 2026-10-27 | [Rothblatt Martine a](/insiders/1106578.md) | Chairperson & CEO, Director, Officer | Sale (S) | 700 | $590.9877 | $413.7k | [Form 4](/filings/0001106578-26-000173.md) |
| 2026-10-27 | [Rothblatt Martine a](/insiders/1106578.md) | Chairperson & CEO, Director, Officer | Sale (S) | 1,003 | $589.9833 | $591.8k | [Form 4](/filings/0001106578-26-000173.md) |
| 2026-10-27 | [Rothblatt Martine a](/insiders/1106578.md) | Chairperson & CEO, Director, Officer | Sale (S) | 1,597 | $588.9463 | $940.5k | [Form 4](/filings/0001106578-26-000173.md) |
| 2026-10-27 | [Rothblatt Martine a](/insiders/1106578.md) | Chairperson & CEO, Director, Officer | Sale (S) | 1,320 | $587.8821 | $776.0k | [Form 4](/filings/0001106578-26-000173.md) |
| 2026-10-27 | [Rothblatt Martine a](/insiders/1106578.md) | Chairperson & CEO, Director, Officer | Sale (S) | 1,417 | $586.9254 | $831.7k | [Form 4](/filings/0001106578-26-000173.md) |
| 2026-10-27 | [Rothblatt Martine a](/insiders/1106578.md) | Chairperson & CEO, Director, Officer | Sale (S) | 470 | $585.7166 | $275.3k | [Form 4](/filings/0001106578-26-000173.md) |
| 2026-10-27 | [Rothblatt Martine a](/insiders/1106578.md) | Chairperson & CEO, Director, Officer | Sale (S) | 1,417 | $584.8289 | $828.7k | [Form 4](/filings/0001106578-26-000173.md) |
| 2026-10-27 | [Rothblatt Martine a](/insiders/1106578.md) | Chairperson & CEO, Director, Officer | Sale (S) | 807 | $583.9443 | $471.2k | [Form 4](/filings/0001106578-26-000173.md) |
| 2026-10-27 | [Rothblatt Martine a](/insiders/1106578.md) | Chairperson & CEO, Director, Officer | Sale (S) | 89 | $582.6649 | $51.9k | [Form 4](/filings/0001106578-26-000173.md) |
| 2026-10-26 | [Rothblatt Martine a](/insiders/1106578.md) | Chairperson & CEO, Director, Officer | Sale (S) | 806 | $592.9168 | $477.9k | [Form 4](/filings/0001106578-26-000172.md) |
| 2026-10-26 | [Rothblatt Martine a](/insiders/1106578.md) | Chairperson & CEO, Director, Officer | Sale (S) | 694 | $591.60 | $410.6k | [Form 4](/filings/0001106578-26-000172.md) |
| 2026-10-26 | [Rothblatt Martine a](/insiders/1106578.md) | Chairperson & CEO, Director, Officer | Sale (S) | 680 | $590.5669 | $401.6k | [Form 4](/filings/0001106578-26-000172.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $2.87bn | 5,294,529 |  | Reduced −105,120 |
| [Avoro Capital Advisors LLC](/funds/1633313.md) | 2026-06-30 | $1.51bn | 2,777,777 |  | Added +147,777 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $1.04bn | 1,919,429 |  | Reduced −84,313 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.04bn | 1,918,256 |  | Reduced −39,283 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $1.03bn | 1,898,064 |  | Added +54,101 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $925.8m | 1,708,739 |  | Reduced −78,280 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $747.2m | 1,379,025 |  | Reduced −885,222 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $538.9m | 996,598 |  | Reduced −236,431 |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $514.0m | 866,930 |  | Not compared |
| [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $450.1m | 831,129 |  | Not compared |

## Recent filings

[All 3,345 filings](/companies/uthr/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-22 | 07:00 ET | [8-K](/filings/0001104659-26-117964.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-117964 |
| 2026-10-14 | 07:00 ET | [8-K](/filings/0001104659-26-115723.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-115723 |
| 2026-09-08 | 17:12 ET | [8-K](/filings/0001104659-26-105953.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-105953 |
| 2026-08-05 | 06:33 ET | [8-K](/filings/0001082554-26-000028.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001082554-26-000028 |
| 2026-08-05 | 06:31 ET | [10-Q](/filings/0001082554-26-000027.md) | Quarterly report, period 2026-06-30 | 0001082554-26-000027 |
| 2026-07-23 | 07:00 ET | [8-K](/filings/0001104659-26-086068.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-086068 |
| 2026-06-29 | 16:32 ET | [8-K](/filings/0001104659-26-078865.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-078865 |
| 2026-05-06 | 06:31 ET | [8-K](/filings/0001082554-26-000021.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001082554-26-000021 |
| 2026-05-06 | 06:30 ET | [10-Q](/filings/0001082554-26-000020.md) | Quarterly report, period 2026-03-31 | 0001082554-26-000020 |
| 2026-04-29 | 06:33 ET | [DEF 14A](/filings/0001082554-26-000009.md) | Proxy statement, period 2026-06-26 | 0001082554-26-000009 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001082554-26-000006.md), filed Feb 25, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/6ec21b37-597a-4fd8-a984-0f62059b0232)

## About the filer

- CIK: 1082554
- Tickers: UTHR
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:32 ET. No prices; not investment advice.